With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?

It would be difficult not to recommend at this time.

HypoG-01 had broad criteria and did not show any differences in outcomes in terms of disease control or toxicity between 40/15 vs 50/25.

RT-CHARM was all reconstructed PMRT patients showed a slightly higher risk of complications with the hypofracti...